APLNR and cancer: To determine whether upregulation of apelin and its receptor contributes to reduced response to anti-VEGF therapy, we used two different endothelial cell lines (EaHY.926 and b.End3) that endogenously express high levels of APJ compared to normal ovarian epithelial or cancer cells (Supplementary Figure 3A).